Bellomo, Giovanni http://orcid.org/0000-0003-0456-5650
Paciotti, Silvia
Concha-Marambio, Luis
Rizzo, Domenico
Wojdaƚa, Anna Lidia
Chiasserini, Davide
Gatticchi, Leonardo
Cerofolini, Linda
Giuntini, Stefano
De Luca, Chiara Maria Giulia
Ma, Yihua
Farris, Carly M.
Pieraccini, Giuseppe
Bologna, Sara
Filidei, Marta
Ravera, Enrico
Lelli, Moreno
Moda, Fabio
Fragai, Marco
Parnetti, Lucilla
Luchinat, Claudio
Funding for this research was provided by:
Parkinson's Disease Foundation (PF-PRF-934916)
Associazione Italiana Ricerca Alzheimer (AGYR2020)
Ministero della Salute (RRC)
Regione Toscana (Progetto Dipartimenti di Eccellenza 2018-2022)
HORIZON EUROPE Marie Sklodowska-Curie Actions (860197 – MIRIADE)
Article History
Received: 26 August 2022
Accepted: 12 March 2023
First Online: 1 April 2023
Declarations
:
: All the procedures involving human subjects were performed following the Helsinki Declaration. All patients and/or their legal representatives gave informed written consent for the lumbar puncture, CSF collection, assessment, analysis, and the inclusion in the study, that was approved by the local Ethics Committee (CEAS n 1287/08), University of Perugia. CSF samples were obtained with the informed consent of all participants.
: Not applicable.
: The authors declare the following competing financial interest(s): Prof. Parnetti served as Member of Advisory Boards for Fujirebio, IBL, Roche and Merck. Dr. Concha, Ms. Farris, and Mr. Ma are inventors on several patents related to SAA technology (PMCA) and are associated to Amprion Inc., a biotech company focused on the commercial utilization of SAA for diagnosis. All the other authors declare no financial and non-financial competing interests.